XBiotech
XBIT
66 hedge funds and large institutions have $56.7M invested in XBiotech in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
18% more funds holding
Funds holding: 56 → 66 (+10)
1.78% more ownership
Funds ownership: 13.71% → 15.49% (+1.8%)
15% less capital invested
Capital invested by funds: $66.6M → $56.7M (-$9.94M)
98% less call options, than puts
Call options by funds: $8K | Put options by funds: $452K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$5.58M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$762K |
| 3 |
HF
HRT Financial
New York
|
+$571K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$535K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$467K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$563K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$350K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$348K |
| 5 |
JP Morgan Chase
New York
|
-$99.1K |
XBIT Hedge Fund Activity: Q3 2021 in Review
66 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2021, worth a combined $56.7M — down 15% from $66.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XBIT positions and 2 closed out — a net gain of 10 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was Oracle Investment Management, opening a new position worth an estimated $5.58M. The largest seller was Wells Fargo, cutting an estimated $1M.
- 66 institutional investors held XBiotech (XBIT) as of Q3 2021, up from 56 in Q2 2021.
- Funds reported $56.7M of XBiotech stock for Q3 2021, down 15% quarter-over-quarter.
- 12 funds opened new XBiotech positions in Q3 2021 and 2 closed out, a net change of +10 holders.
- The largest XBiotech buyer in Q3 2021 was Oracle Investment Management, an estimated $5.58M added.
- The largest XBiotech seller in Q3 2021 was Wells Fargo, an estimated $1M sold.
Based on aggregated 13F filings for Q3 2021.